After having been diagnosed with myeloma in 2019, Vincent Claus got in touch with MPE and joined the Taskforce. In 2022, he joined the Advocate Development Programme (ADP) and has since then been involved in many patient advocacy efforts such as SISAQOL-IMI. Recently with the support of MPE, he launched a specific support group for younger myeloma patients (European Young Myeloma Patients Group). His main fields of interest are the youngest myeloma population, lobbying for early(er) diagnosis and equal treatment approaches across Europe.
The European Commission approves isatuximab + VRd combination therapy for newly diagnosed, transplant ineligible myeloma patients
On 22 January 2025, the European Commission approved an isatuximab combination for the treatment of newly diagnosed myeloma patients who are not eligible for a stem cell transplant in the EU.…